We are an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. Long recognized for our expertise in antibody innovation, our passionate and collaborative team has pioneered antibody-based formats, including bispecific antibodies, antibody-drug conjugates, immune-modulating antibodies, and other modalities for the treatment of cancer and other serious diseases.
Today, we are advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Our quest to turn science into medicine and transform the treatment of cancer and other serious diseases is guided by our core values: a passion for innovation, determination, integrity, working as one team, and respecting each other. When you work at Genmab you'll be part of a warm, fun, dynamic community seeking out and embracing the opportunity to build new and bold futures within a rapidly growing biotechnology company. Genmab is a place where you can be authentically you; you are empowered to innovate, build solutions and execute; you feel cared for and supported. Altogether, this makes working at Genmab an extra[not]ordinary® experience.
Headquartered in Copenhagen, Denmark, Genmab has a strong international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com.
Disclaimer: http://gmab.ly/Jn0e50XWplA
Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world.
Any information expressed by Iovance is subject to the risk factors and information on forward-looking statements contained in its filings with the Securities and Exchange Commission and available here: https://ir.iovance.com/sec-filings
Lengo Therapeutics has been acquired by Blueprint Medicines. Follow @Blueprint Medicines and visit the Blueprint Medicines website to learn more: https://www.blueprintmedicines.com/